Dernières nouvelles pour Third Harmonic Bio (NASDAQ:THRD) Stock

Third Harmonic Bio

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Third Harmonic Bio Inc

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43618804/third-harmonic-bio-announces-phase-1-clinical-results-for-thb335-and-provides-corporate-strategic-" rel="noreferrer noopener">THB335 in healthy volunteers</a>.
The company says the data are expected to support the advancement of THB335 into a Phase 2 trial in chronic spontaneous urticaria (CSU).
Dose-dependent reductions in serum tryptase, a biomarker of mast cell activation, were observed in the MAD cohorts, with mean reductions from baseline ranging from 13% to 84% at Day 15.
THB335 was generally safe and well tolerated in the SAD cohorts. There were 3 subjects in the MAD cohorts with isolated, transient asymptomatic transaminase elevations. Two of the three subjects received a placebo (1 subject in the 21 mg cohort and 1 subject in the 164 mg cohort), and 1 active subject received THB335 in the 164 mg cohort.
Transaminase elevations in the 164 mg cohort were largely consistent in time course and magnitude for the placebo and active subjects.
The company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study in CSU by mid-year 2025.
The company also initiated a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value.
&#8220;As we evaluate the competitive landscape and current market dynamics, we believe the right thing for our stakeholders is to evaluate a full range of strategic transactions and/or business combinations to maximize value creation across all assets in the company&#8230;&#8221; said Natalie Holles, Chief Executive Officer of Third Harmonic Bio.
In conjunction with this announcement, the company is halting all non-THB335 related research and discovery activities and undertaking a reduction in workforce of approximately 50%. As of December 31, 2024, the company had approximately $285 million in cash and cash equivalents.
After accounting for expenses related to THB335 Phase 2 readiness activities, continuing operations, and restructuring costs, Third Harmonic Bio estimates it will have cash and cash equivalents of approximately $262 million to $267 million on June 30, 2025.
In December 2022, Third Harmonic discontinued the Phase 1b study of THB001 in chronic inducible urticaria after observing asymptomatic liver transaminitis in two subjects enrolled in the first dose <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30093276/third-harmonic-bio-stock-plummets-after-trial-discontinuation-on-safety-concerns" rel="noreferrer noopener">cohort of 200mg BID</a>.
Price Action: THRD stock closed at $3.56 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43629559/novartis-to-beef-up-heart-disease-offering-with-3-billion-blackstone-backed-anthos-therapeutics-deal" target="_blank" rel="noreferrer noopener">Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal</a></li>
</ul>

Biotech

News

Health Care

Movers

Trading Ideas

General

THRD

Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape

Morgan Stanley analyst Michael Ulz downgrades Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) from Overweight to Equal-Weight and lowers the price target from $20 to $5.

Downgrades

Price Target

Analyst Ratings

Morgan Stanley Downgrades Third Harmonic Bio to Equal-Weight, Lowers Price Target to $5

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares increased by 49.46% to $0.4. The company's market cap stands at $29.2 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock rose 38.58% to $0.21. The company's market cap stands at $7.1 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 38.06% to $4.28. The market value of their outstanding shares is at $34.2 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock rose 16.35% to $24.55. The company's market cap stands at $2.1 billion. </li>
<li>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) shares increased by 13.06% to $5.54. The company's market cap stands at $118.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares declined by 43.4% to $0.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares fell 29.25% to $3.29. The company's market cap stands at $148.2 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock declined by 26.7% to $0.26. The company's market cap stands at $4.4 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares declined by 18.97% to $15.0. The market value of their outstanding shares is at $39.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 17.54% to $1.88. The company's market cap stands at $4.2 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) stock decreased by 16.77% to $1.39. The company's market cap stands at $101.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

ENTA

HYPR

INAB

LIPO

LIXT

OCEA

TTOO

TVTX

VTVT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

WIIM

Third Harmonic Bio shares are trading lower after Raymond James downgraded the stock from Outperform to Market Perform.

Raymond James analyst Laura Prendergast downgrades Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) from Outperform to Market Perform.

Raymond James Downgrades Third Harmonic Bio to Market Perform

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

<ul>
<li>THB335 Phase 1 data support advancement into Phase 2 clinical trial in&nbsp;chronic spontaneous urticaria (CSU)</li>
<li>Company initiating process to leverage balance sheet strength to&nbsp;maximize shareholder value</li>
<li>Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited)</li>
</ul>

Third Harmonic Bio Says Data From Its Phase 1 Trial Of THB335 In Healthy Volunteers Supports The Advancement Into A Phase 2 Trial In Chronic Spontaneous Urticaria; The Company Is Initiating A Strategic Review Process To Run In Parallel With Phase 2 Readiness Activities To Identify Opportunities To Maximize Shareholder Value

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 64.9% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock moved upwards by 50.47% to $0.22. The market value of their outstanding shares is at $7.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 20.21% to $5.59. The market value of their outstanding shares is at $251.8 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock increased by 15.78% to $2.64. The company's market cap stands at $5.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares increased by 15.26% to $1.51. The market value of their outstanding shares is at $6.0 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 10.53% to $0.11. The company's market cap stands at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares fell 17.4% to $0.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $49.5 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) shares declined by 11.3% to $9.11. The market value of their outstanding shares is at $482.5 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock decreased by 10.75% to $0.61. The market value of their outstanding shares is at $21.5 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 10.62% to $4.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares fell 9.56% to $1.42. The market value of their outstanding shares is at $169.8 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 9.0% to $0.44. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVGR

BDRX

CNSP

DHAI

IVVD

PRLD

SLXN

STOK

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Acelyrin, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) fell sharply in today's <a href="https://www.benzinga.com/quote/SLRN">pre-market trading</a>.
ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
Acelyrin shares tumbled 15.4% to $2.95 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) shares fell 13.2% to $7.00 in pre-market trading.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) fell 12.2% to $10.55 in pre-market trading after jumping 32% on Monday.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) dipped 7.3% to $8.40 in pre-market trading following a 4% gain on Monday.</li>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) fell 6.8% to $10.41 in pre-market trading.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) fell 3.7% to $7.52 in pre-market trading.</li>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) fell 4.8% to $11.36 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 1.7% to $404.26 in pre-market trading. Tesla on Monday reminisced about delivering the first Model 3 cars made at the company's gigafactory in Shanghai.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

Markets

COGT

NPCE

SLRN

TKNO

TSLA

YMAB

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Friday.
Shares of Ingles Markets, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMKTA#NASDAQ">IMKTA</a>) fell in today's pre-market trading after the company reported results for the three and twelve <a href="https://www.benzinga.com/quote/IMKTA/earnings">months ended Sept. 28</a>.
Net sales fell to $1.40 billion for the recent quarter, down from $1.58 billion in the year-ago period.
Ingles Markets shares fell 1.2% to $65.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Viemed Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) shares dipped 6.7% to $7.62 in pre-market trading after gaining 2% on Thursday.</li>
<li>Evotec SE  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 6.6% to $4.56 in pre-market trading following a 2% decline on Thursday.</li>
<li>Nabors Energy Transition Corp. II (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NETD#NASDAQ">NETD</a>) fell 6.3% to $10.11 in pre-market trading.</li>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) fell 4.8% to $10.31 in pre-market trading.</li>
<li>American Public Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) shares declined 4.7% to $21.26 in pre-market trading.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) fell 3% to $24.37 in pre-market trading.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) dipped 2.6% to $13.30 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares slipped 0.7% to $451.12 in pre-market trading after declining around 1.8% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42698100/constellium-viracta-therapeutics-and-3-stocks-to-watch-heading-into-friday">Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

ACIC

APEI

IMKTA

MNSO

NETD

Ingles Markets, Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.28) by 185.71 percent.

Earnings

Earnings Misses

Third Harmonic Bio Q3 2024 GAAP EPS $(0.80) Misses $(0.28) Estimate

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 127.9% to $3.1 during Monday's regular session. The company's market cap stands at $5.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) stock moved upwards by 58.24% to $21.3. The company's market cap stands at $53.1 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 44.04% to $66.36. The market value of their outstanding shares is at $862.2 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock rose 24.27% to $23.96. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 23.42% to $1.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares moved upwards by 22.19% to $57.59. The market value of their outstanding shares is at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 15.8% to $1.98 during Monday's regular session. The company's market cap stands at $10.7 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock declined by 15.6% to $7.12. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares declined by 15.57% to $12.1. The market value of their outstanding shares is at $497.2 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares decreased by 15.52% to $14.87. The market value of their outstanding shares is at $22.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 13.5% to $2.05. The company's market cap stands at $349.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock decreased by 13.3% to $5.35. The market value of their outstanding shares is at $110.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCRX

BSGM

CVKD

DERM

IART

IRON

NGNE

NUWE

OMIC

TVGN

XTLB

12 Health Care Stocks Moving In Monday's Intraday Session

Third Harmonic shares are trading higher on continued strength after the company reported Q2 financial results yesterday. Also, Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $12 to $20.

Morgan Stanley analyst Michael Ulz upgrades Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) from Equal-Weight to Overweight and raises the price target from $12 to $20.

Upgrades

Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20

Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent.

Earnings Beats

Third Harmonic Bio Q2 2024 Adj EPS $(0.19) Beats $(0.27) Estimate

Stifel analyst Alex Thompson initiates coverage on Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) with a Buy rating and announces Price Target of $23.

Initiation

Stifel Initiates Coverage On Third Harmonic Bio with Buy Rating, Announces Price Target of $23

Raymond James analyst Laura Prendergast initiates coverage on Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) with a Outperform rating and announces Price Target of $18.

Raymond James Initiates Coverage On Third Harmonic Bio with Outperform Rating, Announces Price Target of $18

Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.31) by 35.48 percent.

Third Harmonic Bio Q1 2024 Adj EPS $(0.20) Beats $(0.31) Estimate

Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.31) by 45.16 percent. This is a 52.78 percent increase over losses of $(0.36) per share from the same period last year.

Third Harmonic Bio Q4 EPS $(0.17) Beats $(0.31) Estimate

In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Third Harmonic Bio, Inc. (THRD – Research Report)...

Third Harmonic Bio, Inc. (THRD) Receives a Buy from Stifel Nicolaus

In a report released today, Akash Tewari from Jefferies maintained a Hold rating on Third Harmonic Bio, Inc. (THRD – Research Report), with a price...

Cautious Hold Rating for Third Harmonic Bio Amid Competitive Pressure from Blueprint Medicines

Jefferies analyst Akash Tewari lowered the firm's price target on Third Harmonic Bio (THRD) to $7 from $15 and keeps a Hold rating on the shares af...

Third Harmonic Bio price target lowered to $7 from $15 at Jefferies

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers. The...

Third Harmonic Bio announces Phase 1 clinical results for THB335

In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize share...

Third Harmonic halting non-THB335 research, reducing workforce by 50%

Third Harmonic Bio, Inc. ( ($THRD) ) has provided an update. On February 11, 2025, Third Harmonic Bio, Inc. announced a restructuring plan aimed at...

Third Harmonic Bio, Inc. Announces Restructuring Plan

As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm's prior $18 price...

Raymond James downgrades Third Harmonic Bio on uncertainty for only asset

Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-time...

Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James

Third Harmonic Bio, Inc. (THRD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky...

Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns

Morgan Stanley downgraded Third Harmonic Bio (THRD) to Equal Weight from Overweight with a price target of $5, down from $20, after the company ann...

Comments

Third Harmonic Bio

Actualités

Dernières nouvelles pour Third Harmonic Bio (NASDAQ:THRD) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL